Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03562637
Title Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors OBI Pharma, Inc
Indications

triple-receptor negative breast cancer

Therapies

Adagloxad simolenin + OBI-821

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.